6 Health Policy Questions for Post-Election Washington

As votes in key congressional races continue to be counted, here are six policy questions that the Rational Health Practice will be keeping our eyes on.
11/04/26

How Will Democrats Try to Deliver on Health Care Affordability Campaign Promises? 

Health care costs were a key focus for Democratic campaigns across the country and ‘affordability’ was their watchword. Congressional Democratic working groups have spent months compiling policy proposals and will be poised to introduce legislative language early in the year. There appears to be broad Democratic consensus around policy priorities such as reversing Medicaid cuts, restoring ACA subsidies, addressing insurance affordability, and tackling prescription drug pricing in the form of Biden-era policies such as out-of-pocket cost caps, drug price negotiation, and additional pharmacy benefit manager (PBM) reforms. Democrats seem likely to move quickly to pass a health care affordability package without regard for bipartisanship and force President Trump to decide whether his legacy is best served by making a deal with Democrats or standing firm on the legacy of the 2025 One Big Beautiful Bill Act.

How will Democrats Exercise Congressional Oversight and Investigation Authority? 

Congressional Democrats have already begun to signal potential oversight and investigations on a broad range of health care topics, including the contents of the Administration’s most-favored nation (MFN) drug pricing deals, DOGE-era cuts to basic health research and agency staffing, and the impact of private equity, consolidation, and vertical integration in health care. 

Who Will Lead Key Committees? 

The coming months will see jockeying for gavels and leadership roles on key health policy and oversight committees. Senator Bernie Sanders (I-VT) is expected to regain the gavel on Senate HELP. Senator Ron Wyden (D-OR), who is expected to chair the Senate Finance Committee, today promised that Democrats will “create a new foundation for America’s health care system that guarantees health care for all, gives Americans cheaper and better health care, and ends the corporate chokehold on our nation’s health care system.” Meanwhile, Republican retirements and electoral defeats have upended existing Republican leadership of some key committees and have created new leadership opportunities within the Republican conference.

Did the MAHA Movement Have Its Waterloo (Iowa) Moment? 

The results of the midterm elections have been widely characterized as a blow to the Make America Healthy Again (MAHA) movement. Despite its failure to elect allies in states like Iowa, however, it may be premature to write the political obituary of the MAHA movement. Prominent Democrats such as Representative Alexandria Ocasio-Cortez (D-NY) and Senator Cory Booker (D-NJ) began courting MAHA-aligned organizations and voters before the midterms, and many of the ideas driving the modern MAHA movement have historical roots in far-left politics. It is worth monitoring whether MAHA leaders seek common ground or confrontation with newly elected doctors and scientists such as Senators-elect Annie Andrews (D-SC) and Abdul El-Sayed (D-MI), and Representative-elect Richard Pan (D-CA), a pediatrician who has spent more than a decade battling the anti-vaccine forebearers of the MAHA movement in California.

Are There Any Health Care ‘Horseshoe’ Issues? 

Beyond basic health care affordability provisions, are there other populist health policy ideas that can generate momentum among unlikely bipartisan fellow travelers in Washington? CVS today already pointed to the ‘Break Up Big Medicine Act’ from Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) as one reason it has decided to break up its business into two separate companies. MFN drug pricing has its roots in progressive Democratic efforts to use international price comparisons to reduce prescription drug costs, an approach the Trump Administration has since embraced through agreements with leading pharmaceutical manufacturers. Would the Trump Administration support codifying MFN deals in the 120th Congress, or will Democratic scrutiny of the deals kill potential legislation before it gets out of the gate? 

Is Medicare for All Up or Down? 

Progressive wins will give new life to the debate around Medicare for All and help to ensure that it remains part of the national health policy discourse heading into the 2028 presidential election cycle. However, Medicare for All remains unlikely to pass as part of the 120th Congress: larger-than-expected congressional majorities mean that Democrats will be less beholden to the far left of the party and many of the newly elected Democrats in competitive districts may be less likely to support Medicare for All than their counterparts in safe seats.

The Rational Health Practice will continue to monitor the aftermath of the election and its health policy implications for leading health care industries and companies. If it would be helpful to talk through opportunities and risks around the new Congress, as well as how to build an integrated campaign to reach new Members and influence the health policy agenda in Washington, please let us know.

Related Posts